Drug Trial Radar · NCT07213609
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
47
Planned (sponsor's estimate)
Start
Oct 20, 2025
Primary completion
Sep 28, 2028
Study completion Oct 27, 2028
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential combinations may be included in future amendments to the protocol) with other anti-cancer agents can decrease tumor size, is safe, well-tolerated, and how the drug is processed in the body over time.
Conditions
- Neoplasms, Colorectal
- Neoplasms
Interventions
GSK5460025Drug
GSK5460025 will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of participants with dose limiting toxicities (DLTs) per dose levelTime frame: Up to 28 days
- Part 1: Number of participants with treatment emergent serious adverse events (TESAEs) and treatment emergent adverse events (TEAEs) by severity per dose levelTime frame: Up to approximately 33 months
- Part 1: Number of participants with TESAEs and TEAEs by severity per dose level during DLT observation periodTime frame: Up to 28 days
- Part 1: Number of participants with dosage modifications due to TEAEs per dose levelTime frame: Up to approximately 33 months
- Part 2: Objective Response Rate (ORR)Time frame: Up to approximately 33 months
Locations
27 sites in 9 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Aurora, Colorado · Recruiting
GSK Investigational Site
Detroit, Michigan · Recruiting
GSK Investigational Site
Canton, Ohio · Recruiting
GSK Investigational Site
Nashville, Tennessee · Recruiting
GSK Investigational Site
Hamilton, Ontario, Canada · Recruiting
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
København Ø, Capital Region, Denmark · Recruiting
GSK Investigational Site
Lyon, France · Recruiting
GSK Investigational Site
Saint-Herblain, France · Recruiting
GSK Investigational Site
Villejuif, France · Recruiting
GSK Investigational Site
Milan, Italy · Recruiting
GSK Investigational Site
Milan, Italy · Recruiting
GSK Investigational Site
Chiba, Japan · Recruiting
GSK Investigational Site
Osaka, Japan · Recruiting
GSK Investigational Site
Tokyo, Japan · Recruiting
GSK Investigational Site
Tokyo, Japan · Recruiting
GSK Investigational Site
Amsterdam, Netherlands · Recruiting
GSK Investigational Site
Utrecht, Netherlands · Recruiting
GSK Investigational Site
Barcelona, Spain · Recruiting
GSK Investigational Site
Madrid, Spain · Recruiting
GSK Investigational Site
Madrid, Spain · Recruiting
GSK Investigational Site
Madrid, Spain · Recruiting
GSK Investigational Site
Madrid, Spain · Recruiting
GSK Investigational Site
Lund, Sweden · Recruiting
GSK Investigational Site
Stockholm, Sweden · Recruiting
GSK Investigational Site
Uppsala, Sweden · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.